Shares of Quanterix Corp (NASDAQ:QTRX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a one year consensus price target of $25.67 for the company and are expecting that the company will post ($0.26) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Quanterix an industry rank of 171 out of 265 based on the ratings given to related companies.
Several research analysts have recently issued reports on QTRX shares. BTIG Research started coverage on shares of Quanterix in a research note on Tuesday, January 2nd. They issued a “buy” rating and a $26.00 target price on the stock. ValuEngine upgraded shares of Quanterix from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Leerink Swann started coverage on shares of Quanterix in a research note on Tuesday, January 2nd. They issued an “outperform” rating and a $27.00 target price on the stock. Cowen started coverage on shares of Quanterix in a research note on Tuesday, January 2nd. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase started coverage on shares of Quanterix in a research note on Tuesday, January 2nd. They issued an “overweight” rating on the stock.
QTRX traded up $0.07 during midday trading on Thursday, reaching $16.31. The company’s stock had a trading volume of 47,566 shares, compared to its average volume of 128,341. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.35 and a current ratio of 4.53. Quanterix has a 1 year low of $15.56 and a 1 year high of $24.81.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and SR-X system that supports the detection capability of approximately six biomarkers per test.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.